Sotatercept Reduced Morbidity in CTD-PAH Analysis: Rogerio Souza, MD, PhD

Why It Matters

Sotatercept’s demonstrated efficacy offers a new therapeutic option for CTD‑PAH, a subgroup with historically poor outcomes, potentially reducing hospitalizations, transplants and overall mortality.

Key Takeaways

• Sotatercept cut first morbidity/mortality events in CTD‑PAH trials
• Benefit observed despite patients on double or triple background therapy
• Pooled data from STELLAR, ZENITH, HYPERION support fourth‑pathway approach
• Findings presented at ATS 2026 conference in Orlando, Florida
• Experts call it a step forward for high‑risk CTD‑PAH patients

Pulse Analysis

Connective tissue disease‑associated pulmonary arterial hypertension (CTD‑PAH) remains one of the most lethal subsets of PAH, with patients often juggling scleroderma, lupus, Sjögren’s or rheumatoid arthritis alongside severe vascular remodeling. Conventional regimens rely on endothelin receptor antagonists, phosphodiesterase‑5 inhibitors and prostacyclin analogues, yet mortality rates exceed 15 % within three years. The disease’s multi‑system nature limits the efficacy of vasodilators alone, prompting clinicians to search for therapies that address the underlying proliferative pathways driving arterial thickening.

Sotatercept, a recombinant fusion protein that traps activin‑type ligands, targets the bone morphogenetic protein (BMP) signaling axis, representing the emerging “fourth pathway” in PAH treatment. The pooled analysis of the phase‑3 STELLAR, ZENITH and HYPERION trials—collectively enrolling over 800 CTD‑PAH patients—demonstrated a 30 % relative reduction in first major morbidity or mortality events versus placebo, even when participants were already on double‑ or triple‑background therapy. Safety signals were comparable to earlier PAH cohorts, with mild anemia being the most frequent adverse event.

These results, unveiled at the American Thoracic Society 2026 meeting, could reshape prescribing habits for high‑risk CTD‑PAH populations and accelerate regulatory submissions worldwide. Payers may view sotatercept as a value‑adding add‑on, given its potential to lower hospitalization and transplant rates, which are costly drivers of overall health‑care spend. Moreover, the data bolster the case for broader combination strategies that integrate anti‑proliferative agents with traditional vasodilators, a trend likely to influence upcoming guideline revisions and stimulate further research into BMP‑targeted drugs.